A National Institute of Health-supported study found that statins, a class of cholesterol-lowering medications, may offset the high risk of cardiovascular disease in people living with […]
Abstract Background The risk of cardiovascular disease is increased among persons with human immunodeficiency virus (HIV), so data regarding primary prevention strategies in this population are […]
Abstract Background Pericoronary adipose tissue (PCAT) may influence plaque development through inflammatory mechanisms. We assessed PCAT density, as a measure of pericoronary inflammation, in relationship to […]
By Priya Venkatesan The REPRIEVE trial has shown a benefit of statins in reducing the risk of cardiovascular events in people living with HIV, but many […]
Abstract Objective Skeletal muscle quality and mass are important for maintaining physical function during advancing age. We leveraged baseline data from REPRIEVE to evaluate whether paraspinal muscle density […]
By Emily Harris People with HIV and a low to moderate traditional risk of cardiovascular disease who took a daily 4-mg dose of pitavastatin reduced their risk […]
By Megan Brooks An international clinical trial testing statin therapy for primary cardiovascular prevention in people living with HIV has been stopped early due to strong […]
By Shelley Wood HIV is merely a “risk modifier” in current guidelines; these results pave the way for a new primary-prevention indication for statins. Read the […]
A National Institute of Health-supported study found that statins, a class of cholesterol-lowering medications, may offset the high risk of cardiovascular disease in people living with […]
Abstract Background The risk of cardiovascular disease is increased among persons with human immunodeficiency virus (HIV), so data regarding primary prevention strategies in this population are […]
Abstract Background Pericoronary adipose tissue (PCAT) may influence plaque development through inflammatory mechanisms. We assessed PCAT density, as a measure of pericoronary inflammation, in relationship to […]
By Priya Venkatesan The REPRIEVE trial has shown a benefit of statins in reducing the risk of cardiovascular events in people living with HIV, but many […]
Abstract Objective Skeletal muscle quality and mass are important for maintaining physical function during advancing age. We leveraged baseline data from REPRIEVE to evaluate whether paraspinal muscle density […]
By Emily Harris People with HIV and a low to moderate traditional risk of cardiovascular disease who took a daily 4-mg dose of pitavastatin reduced their risk […]
By Megan Brooks An international clinical trial testing statin therapy for primary cardiovascular prevention in people living with HIV has been stopped early due to strong […]
By Shelley Wood HIV is merely a “risk modifier” in current guidelines; these results pave the way for a new primary-prevention indication for statins. Read the […]